{
    "clinical_study": {
        "@rank": "104305", 
        "arm_group": [
            {
                "arm_group_label": "nifedipine CR tablets (Xin Ran)", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will take a nifedipine controlled-release tablet (30 mg, Xin Ran) orally in every morning for a 12-week treatment period."
            }, 
            {
                "arm_group_label": "nifedipine CR tablets (Adalat)", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will take a nifedipine controlled-release tablet (30 mg, Adalat) orally in every morning for a 12-week treatment period."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare nifedipine controlled-release (CR) tablets (Xin Ran)\n      with nifedipine controlled-release tablets (Adalat\uff09in the treatment of mild to moderate\n      essential hypertension."
        }, 
        "brief_title": "Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Essential Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Voluntarily participate and must sign informed consent form\n\n          -  Mild to moderate essential hypertension (SBP 140-179 mmHg and/or DBP 90-109 mmHg)\n\n          -  Average DBP measured by 24-hour ambulatory blood pressure monitoring (ABPM) \u226580 mmHg\n\n        Exclusion Criteria:\n\n          -  Secondary hypertension and malignant hypertension\n\n          -  Pregnant or nursing women, or patients that cannot guarantee to take effective\n             contraception measures\n\n          -  Baseline SBP\u2265180 mmHg or DBP\u2265110 mmHg, or patients with cerebral, cardiac or renal\n             complications\n\n          -  Have following complications: cerebrovascular accident within 6 months, myocardial\n             infarction or cardiac failure, macroaneurysm or dissecting aneurysm, definite angina,\n             A-V block of grade 2 or higher, sick sinus syndrome, atrial fibrillation or other\n             malignant arrhythmia\n\n          -  Clinical significant diseases of heart, lung, liver, kidney and hematologic system or\n             malignant tumors, HIV infection, uncontrolled diabetes (fasting blood glucose \u22657.0\n             mmol/L, 2-hour postprandial blood glucose \u22657.8 mmol/L)\n\n          -  Kock pouch\n\n          -  Sever gastrointestinal stenosis\n\n          -  Abnormal laboratory values with clinical significance, including serum potassium <3.5\n             or >5.5 mmol/L, glutamic-pyruvic transaminase (ALT) or glutamic oxalacetic\n             transaminase (AST) >2-fold upper limit of normal (ULN), Cr >ULN\n\n          -  Uric acid >ULN with the diagnosis of gout\n\n          -  Gastrointestinal abnormalities or surgery that may interfere with drug absorption\n\n          -  Hyperthyroidism or hypothyroidism\n\n          -  Allergic to any ingredient or metabolite of investigational drug or drugs of similar\n             structure\n\n          -  Heavy smokers (>25 cigarettes every day), alcoholics (>250 ml liquor every day), drug\n             addicts\n\n          -  Psychological diseases, acrasia, cannot express explicitly\n\n          -  Patients whose mood may be affected by variations in blood pressure, which in turn\n             increases blood pressure\n\n          -  Anxiety disorders, depression or cannot follow study protocol\n\n          -  BMI >30\n\n          -  Night shift, irregular sleep patterns or insomnia\n\n          -  participate in other clinical trials within 3 months\n\n          -  other conditions that investigators consider unsuitable for participation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02031861", 
            "org_study_id": "CH-004PIV"
        }, 
        "intervention": [
            {
                "arm_group_label": "nifedipine CR tablets (Xin Ran)", 
                "intervention_name": "nifedipine CR tablets (Xin Ran)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "nifedipine CR tablets (Adalat)", 
                "intervention_name": "nifedipine CR tablets (Adalat)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Nifedipine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200025"
                }, 
                "name": "Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Random, Open Label, Active Comparator-controlled Parallel Study to Evaluate the Efficacy of Nifedipine Controlled-released Tablets (Xin Ran) in Patients With Mild to Moderate Essential Hypertension", 
        "other_outcome": {
            "measure": "clinical laboratory test and adverse event", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "overall_contact": {
            "last_name": "Chongping\u00b7 Liu", 
            "phone": "(86)21-62102186"
        }, 
        "overall_official": {
            "affiliation": "Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School", 
            "last_name": "Pingjin Gao", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "change in morning blood pressure surge from baseline", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "change in central systolic blood pressure, central diastolic blood pressure, central pulse pressure and augmentation index from baseline", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02031861"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "change in morning blood pressure from baseline", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "T/P ratio", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "average reduction in systolic blood pressure from 18 to 24 hours after administration", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "average reduction in diastolic blood pressure from 18 to 24 hours after administration", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "smoothness index", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "change in morning blood pressure surge from baseline", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "change in central systolic blood pressure, central diastolic blood pressure, central pulse pressure and augmentation index from baseline", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "change in morning blood pressure from baseline", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "T/P ratio", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "average reduction in systolic blood pressure from 18 to 24 hours after administration", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "average reduction in diastolic blood pressure from 18 to 24 hours after administration", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "smoothness index", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "change in systolic blood pressure (SBP) from baseline", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "change in diastolic blood pressure (DBP) from baseline", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Shanghai Shyndec Pharmaceutical Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shanghai Shyndec Pharmaceutical Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}